Abstract Library

#3033 First-in-Korea Clinical Trial of Lu-177-DOTATATE in Patients with Inoperable, Progressive Somatostatin Receptor-Positive, Metastatic or Locally Advanced Neuroendocrine Tumor (SNU-KB-01)

Introduction: Peptide receptor radionuclide therapy (PRRT) based on Lu-177 DOTATATE is currently used worldwide as a treatment option for neuroendocrine tumor patients. But until now, no PRRT has been approved by the Korea Food and Drug Administration (KFDA). Thus, neuroendocrine tumor patients in Korea have severely limited access to the treatment. To provide treatment opportunities, we have planned a First-in-Korea phase I clinical trial of SNU-KB-01, no-carrier added Lu-177 labeled DOTATATE.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Suh M, Cheon G, Lee D,

Keywords: PRRT, clinical trial, Neuroendocrine tumor, Lu-177-DOTATATE,

#2839 The Second Revision of Clinical Practice Guidelines in GEP-NEN in Japan

Introduction: Japanese Neuroendocrine Tumor Society (JNETS) has published the first edition of clinical practice guidelines in gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) in 2015. Then, according to an update on the diagnosis and management of GEP-NEN in Japan. Revised clinical practice guidelines, the second edition, has just published in 2019.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ito T, Masui T, Komoto I,

Keywords: GEP-NEN, Guideline, Japan,

#2164 A Case of Carcinoid Induced Heart Disease

Introduction: Carcinoid Heart disease is a common disease with neuroendocrine malignancies that invade the liver due to the paraneoplastic effects of vasoactive substances such as 5-hydroxytryptamine, histamine and tachykinins released by malignant cells rather than any direct metastatic involvement of the heart.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Ashraff S

Authors: Ashraff S, MacGowan G, Perros P, James A,

Keywords: Carcinoid, Heart disease, heart valves,

#1657 Establishment of Japan NeuroEndocrine Tumor Society and Its Registration System

Introduction: In 2012, many nation-wide gastroenterologists, endocrinologists, surgeons, radiologists and pathologists have established Japan NeuroEndocrine Tumor Society (JNETS) in Japan. JNETS is now composed of 304 institutes.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Masui T

Authors: Masui T, Imamura M, Ito T, Unno M, Okusaka T,

Keywords: registry system, Japan,,

#1582 Utility of Serum Chromogranin B Compared with Chromogranin A as a Biomarker in Japanese Patients with Pancreatic Neuroendocrine Tumors

Introduction: Currently, serum chromogranin A (CgA) is used as a biomarker for pancreatic neuroendocrine tumors (pNET); however, oral use of a proton pump inhibitor (PPI) and renal impairment can affect CgA.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Miki M, Ito T, Hijioka M, Kawabe K, Jensen R,

Keywords: Pancreatic neuroendocrine tumors, Chromogranin A, Chromogranin B,